Ashish Gulati has more than 20 years of experience in the healthcare field: after a career in research at the All India Institute of Medical Sciences in New Delhi in 2000, he joined Roche as a Medical Manager in Oncology and Rheumatology. After 8 years at Roche, he joined AstraZeneca as Senior Global Medical Officer in Gaithersburg. He then joined Abbvie in 2018 as Medical Director specialized in Myeloid & MM and finally Takeda Oncology in 2020 as Global Medical Leader, specialized in lung cancer. During his career, he participated in the global launch for key molecules in Solid Tumor and Hematological Malignancies: (Venetoclax for AML, Mobocertinib for exon 20 ins NSCLC, Avastin for GBM, mRCC, Nanoxel for MBC, Benralizumab for SA, Tocilizumab for RA)
Ashish Gulati first obtained a doctorate in medicine at the University of Aarhus. He then went on to Berkeley, Harvard and King's College to study leukemia, particularly Myeloid Malignancies. As previously mentioned, he was also a resident at the All India Institute of Medical Sciences in New Delhi.